跳至主要内容
临床试验/NCT06243029
NCT06243029进行中(未招募)不适用

Clinical Observational Study of Remote, Non-invasive, Multidomain Endpoints in Patients Recovering From Acute Decompensated Heart Failure

AstraZeneca3 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2024年1月8日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
AstraZeneca
入组人数
67
试验地点
3
主要终点
Change in patch-measured variables between baseline and follow-up at 6-8 weeks (multiple variables) using the ECG patch.

研究概览

简要总结

This study aims to evaluate the utility of a wearable heart monitoring patch that can be worn on the body to collect various measurements related to heart failure and develop a concept to potentially be used as a new measurement. It is crucial to test out new ways that make it easier to do research for new drugs and increase our chances of knowing how well they will work early on in the development process. Results from this study will be useful in planning future development programs for drugs aimed at treating patients with heart disease.

This study will be conducted in a single hospital, it is non-randomised (not chosen by chance), exploratory, study in the United Kingdom (University Hospitals of Leicester NHS Trust). It aims to involve up to 80 men and women recently admitted due to sudden, severe heart failure symptoms. Participants will be part of the study for about two months, with one hospital visit after discharge, as commonly done in heart failure centres.

  • Visit 1 (Pre-Screening/Screening/Enrolment) will assess the participant's eligibility for participating in the study and for collecting data following hospitalisation for acute decompensated heart failure (ADHF). Participants will be trained and receive an ECG patch to wear from that moment onwards at home for a period of 4 to 7 days.
  • Visit 2 (Follow-up visit) will be conducted approximately 6-8 weeks post Visit 1 and this will be the final study-related site visit. Participants will receive an ECG patch to wear at home for a second time for a period of 4 to 7 days.
  • Visit 3 (Review of Medical Records). It is a review of the health status using medical records by the study team. The participant is not expected to attend the hospital for any appointments

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women aged 18 years or older
  • Confirmed diagnosis of heart failure according to the latest ESC criteria
  • Primary cause of hospitalisation due to decompensated heart failure
  • Willing and able to complete all visits and assessments as per protocol
  • Provision of signed and dated, written informed consent before any study-specific procedures.

排除标准

  • Receiving renal replacement therapy
  • Implanted cardiac (or other) device in-situ, cardiac pacemaker, defibrillator, or other implanted electronic devices or other ventricular assist device in situ
  • Currently receiving chemotherapy
  • Receiving end-of-life care
  • Active severe infection: individuals with an active severe infection, as determined by the PI's clinical judgment, will not be eligible for study participation
  • Hypersensitivity to patch adhesive/ materials in the patch
  • Skin condition or damage that prevents wearing of the patch.

结局指标

主要结局

Change in patch-measured variables between baseline and follow-up at 6-8 weeks (multiple variables) using the ECG patch.

时间窗: 6-8 weeks

次要结局

  • Correlation between clinical parameters e.g. NT-pro BNP, KCCQ, BP, HR and the patch variables using data from Visit 1 (multiple comparisons).(6-8 weeks)
  • Correlation between change in NT-proBNP, BP, HR, body weight, peripheral oedema extent, NYHA class etc. and change in the patch variables (multiple comparisons).(6-8 weeks)
  • Correlation between a change in ECG patch variables (multiple) and change in KCCQ at 6-8 weeks after discharge from hospital following admission for ADHF.(6-8 weeks)
  • Correlation between change in one minute sit to stand test, frailty score, hand grip test and the change in patch variables (multiple comparisons).(6-8 weeks)
  • Data completeness overall and per ECG patch variable, participant adherence, signal to noise ratio, day versus night assessment of quality using the ECG patch.(6-8 weeks)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验